Efficacy and Safety of AP 12009 in Adult Patients with Recurrent or Refractory Anaplastic Astrocytoma (WHO grade III) or Secondary Glioblastoma (WHO grade IV) as Compared to Standard Chemotherapy: A Randomized, Actively Controlled, Open Label Clinical Phase III Study.

Trial Profile

Efficacy and Safety of AP 12009 in Adult Patients with Recurrent or Refractory Anaplastic Astrocytoma (WHO grade III) or Secondary Glioblastoma (WHO grade IV) as Compared to Standard Chemotherapy: A Randomized, Actively Controlled, Open Label Clinical Phase III Study.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Trabedersen (Primary) ; Carmustine; Lomustine; Temozolomide
  • Indications Anaplastic astrocytoma; Glioblastoma
  • Focus Registrational; Therapeutic Use
  • Acronyms SAPPHIRE
  • Sponsors Isarna Therapeutics
  • Most Recent Events

    • 06 Jun 2012 New source identified and integrated (German Clinical Trials Register; DRKS00003686).
    • 28 Mar 2012 Actual patient number is 27 according to ClinicalTrials.gov.
    • 28 Mar 2012 Actual end date (Apr 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top